Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | SUITE 800, 4800 MONTGOMERY LANE BETHESDA MD 20814 |
Tel: | N/A |
Website: | https://nwbio.com |
IR: | See website |
Key People | ||
Linda F. Powers Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer | Leslie J. Goldman Senior Vice President, General Counsel | Alton L. Boynton Chief Scientific Officer, Corporate Secretary, Director | Marnix L. Bosch Chief Technical Officer |
Business Overview |
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company's wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH. |
Financial Overview |
For the fiscal year ended 31 December 2023, Northwest Biotherapeutics Inc revenues increased 15% to $1.9M. Net loss applicable to common stockholders decreased 39% to $64.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of derivative liabi increase from $25.8M (expense) to $3.6M (income). |
Employees: | 25 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $604.89M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.93M as of Dec 31, 2023 |
EBITDA (TTM): | -$53.98M as of Dec 31, 2023 |
Net annual income (TTM): | -$64.37M as of Dec 31, 2023 |
Free cash flow (TTM): | -$57.07M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $38.67M as of Dec 31, 2023 |
Shares outstanding: | 1,189,970,308 as of Feb 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |